Zimmer Biomet’s (ZBH) Buy Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a research note published on Thursday morning,Benzinga reports. They currently have a $112.00 price objective on the medical equipment provider’s stock.

Other analysts also recently issued research reports about the company. UBS Group cut their target price on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a research note on Thursday, November 6th. Barclays reduced their price objective on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a report on Wednesday, November 5th. Stifel Nicolaus set a $110.00 target price on shares of Zimmer Biomet in a research note on Wednesday, November 5th. Johnson Rice set a $112.00 price target on shares of Zimmer Biomet in a research note on Wednesday, November 5th. Finally, Robert W. Baird reiterated a “neutral” rating and set a $100.00 price objective (down previously from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $107.33.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $92.83 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. The firm has a market capitalization of $18.40 billion, a PE ratio of 22.98, a P/E/G ratio of 2.37 and a beta of 0.62. Zimmer Biomet has a 1-year low of $85.33 and a 1-year high of $114.44. The business’s fifty day moving average price is $92.04 and its two-hundred day moving average price is $96.59.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping the consensus estimate of $1.88 by $0.02. The business had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts expect that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 23.76%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Key Financial Inc boosted its stake in shares of Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. lifted its holdings in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC boosted its position in shares of Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 149 shares during the period. Root Financial Partners LLC purchased a new position in Zimmer Biomet in the 3rd quarter worth about $31,000. Finally, Mather Group LLC. acquired a new stake in Zimmer Biomet during the 3rd quarter worth about $36,000. Institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.